The drink has been trialled in select European markets for “some months” and contains 1200mg of DHA (docosahexaenoic acid) and 300mg of EPA (eicosapentaenoic acid) - omega-3 forms that have been most strongly linked to brain and heart health.
It is being sold through accredited UK pharmacies that conduct short e-learning courses so its staff are informed about the product’s use and benefits as of today.
Nutricia said three clinical trials had been carried out with the product – all of which had showed a benefit to those sufferings early signs of dementia, of which Alzheimer’s is the most common form. Others were ongoing.
The product is regulated under EU Food for Special Medical Purposes laws that are under review at the moment, and those considering using it must first have a recommendation from a doctor or other medical professional.
Each 125ml bottle of Souvenaid, as it is called, will sell for £3.49 (€4.20) in strawberry or vanilla flavours.
It is estimated 800,000 Brits that suffer from dementia, of which Alzheimer’s is the most common form.
“A diagnosis of dementia is devastating both for those with the condition and their families and carers,” said Barbara Stephens, Dementia UK CEO.
“Early stage intervention is important for maximising choices and enabling people with dementia and their carers to lead healthier lives for longer.”
Other ingredients in the formulation include uridine monophosphate, choline, phospholipids and B vitamins.
A spokesperson said the product was intended to complement rather than replace conventional treatments.